SMW Free Realtime Trade Alerts -- Our Last 2 Trade Alerts were VII and NFEC, easy 40-75% wins in minutes, Join Today for FREE!!

Biogen Inc.
(NASDAQ : BIIB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading BIIB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.92%81.041.6%$909.32m
BIIBBiogen Inc.
0.06%288.521.2%$563.92m
CELGCelgene Corporation
2.63%110.951.1%$496.64m
AMGNAmgen Inc.
0.36%171.291.2%$486.33m
REGNRegeneron Pharmaceuticals, Inc.
-0.98%411.023.1%$311.27m
ALXNAlexion Pharmaceuticals, Inc.
0.31%130.192.6%$250.99m
BMRNBioMarin Pharmaceutical Inc.
0.32%98.403.9%$222.01m
TSROTESARO, Inc.
-1.01%92.4418.0%$217.89m
ILMNIllumina, Inc.
2.31%166.005.1%$188.92m
VRTXVertex Pharmaceuticals Incorporated
-0.20%95.821.7%$136.58m
MDVNMedivation, Inc.
-0.34%62.342.6%$123.87m
JUNOJuno Therapeutics, Inc.
-2.07%29.747.9%$103.49m
EXASExact Sciences Corporation
0.42%16.8928.8%$95.28m
AAgilent Technologies, Inc.
0.42%47.461.9%$89.59m
INCYIncyte Corporation
-0.74%88.072.2%$76.18m

Company Profile

Biogen, Inc. is a global biotechnology company, which develops markets and manufactures therapies for people living with neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded on November 12, 2003 and is headquartered in Cambridge, MA.